BBNX

#2521
Beta Bionics, Inc. - Common Stock
19.7 2 USD
+0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
19.72
19.72
Intervallo Annuale
8.80
32.71
Variazione giornaliera
+0.92%
Variazione Mensile
+40.96%
Variazione di 6 mesi
+59.16%
Variazione Annuale
-7.24%
Chiusura Precedente
19.5 4
Open
19.7 2
Minimo
19.7 2
Massimo
19.7 2
Volume
43
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Beta Bionics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Beta Bionics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Beta Bionics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Beta Bionics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Beta Bionics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Beta Bionics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Beta Bionics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Beta Bionics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Beta Bionics, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Beta Bionics, Inc. annual report, FY2025
10-K

Beta Bionics, Inc. current report, Q2 FY2026

Full document

Beta Bionics, Inc. 8-K Summary

Business Context and Reporting Period

This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held by Beta Bionics, Inc. on May 21, 2026. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Irvine, California.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.

Material Changes and Voting Results

As of the record date (March 23, 2026), there were 44,561,695 outstanding shares of common stock. A quorum of 36,061,048 shares was represented at the meeting. Two proposals were submitted and approved:

  • Proposal 1: Election of Directors
    • Sean D. Carney: Elected with 30,659,060 votes for, 608,992 votes withheld, and 4,792,996 broker non-votes.
    • Christy Jones: Elected with 25,865,542 votes for, 5,402,510 votes withheld, and 4,792,996 broker non-votes.
    • Both directors were elected to serve until the 2029 Annual Meeting.
  • Proposal 2: Ratification of Independent Auditor
    • Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
    • Votes For: 36,011,432
    • Votes Against: 41,527
    • Abstentions: 8,089

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is limited to the submission of matters to a vote of security holders.

Key Facts for Investor Verification

  • Verify the tenure of newly elected directors Sean D. Carney and Christy Jones (until 2029).
  • Confirm the appointment of Ernst & Young LLP as the auditor for the fiscal year ending December 31, 2026.
  • Note the significant number of votes withheld for Christy Jones (5,402,510) compared to Sean D. Carney (608,992).
  • Review the definitive proxy statement filed on April 10, 2026, for detailed background on the proposals.